All Stories

  1. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays
  2. International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain
  3. A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
  4. Protease-activated receptor 4 is more important than protease-activated receptor 1 for the thrombin-induced procoagulant effect on platelets
  5. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate
  6. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti‐FXa assays
  7. Contact activation: important to consider when measuring the contribution of tissue factor‐bearing microparticles to thrombin generation using phospholipid‐containing reagents